In the present analysis we evaluated the long-term impact on the course of HIV infection when a dual anti-HIV gene construct (CCR5 entry inhibitor +C46 fusion inhibitor) is delivered to either CD4+T cells or to CD34+ HSC. This evidence concerns the gene CCR5 and HIV infectious disease.